Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.2160
UNCHANGED
Streaming Delayed Price
Updated: 3:55 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study
April 28, 2022
Via
Investor Brand Network
Plants Could Unlock Future Cancer Therapies
April 25, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers
April 22, 2022
Via
Investor Brand Network
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
April 13, 2022
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and...
From
JTC Team, LLC
Via
AccessWire
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
April 13, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
April 11, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 06, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights at Virtual Growth Conference
April 05, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
April 04, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at 2022 Virtual Growth Conference
March 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference
March 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Discusses Milestone in Advancing Berubicin
March 18, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
March 17, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate
March 10, 2022
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders
March 09, 2022
Via
Investor Brand Network
Exposures
Product Safety
CNS Pharmaceuticals (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session
March 08, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference
March 07, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update
March 04, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update
March 03, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Laying Foundation for Potentially Pivotal Global Trial
February 03, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial
February 02, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Marks Milestone in Pursuit of Berubicin Approval for GBM
January 26, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement
January 25, 2022
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference
January 21, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference
January 20, 2022
Via
Investor Brand Network
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...
From
JTC Team, LLC
Via
AccessWire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.